Business
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney WINSTON-SALEM, NC, July 20, 2022 (GLOBE NEWSWIRE) --
About this update from Prokidney Corp.
[{"type":"text","content":"Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney\nWINSTON-SALEM, NC, July 20, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on Chronic Kidney Disease (CKD), announces the appointment of nephrologist Kerry Cooper, M.D. as Senior Vice President of Medical Affairs. Dr. Cooper, who will report to Chief Medical Officer Dr. Libbie McKenzie, joins ProKidney from AstraZeneca, where he was Vice President, U.S. Medical Affairs Renal Division. He led medical teams on nephrology programs, including Lokelma®, and contributed to cross functional teams advancing therapeutics utilized by CKD patients. Dr. Cooper has strong relationships with global kidney advocacy organizations and CKD community leaders. Dr. Libbie McKenzie, CMO of ProKidney, said: “On behalf of our entire team, I am delighted to welcome Dr. Cooper to ProKidney. His deep experience gained through nearly 40 years in clinical practice and industry will be invaluable as we continue to advance REACT™ through multiple mid- and late-stage clinical studies. He has a wealth of nephrology expertise, both treating patients and leading the development of therapies for CKD, and we look forward to leveraging his extensive capabilities as we enter our next phase of growth and development.” Prior to joining AstraZeneca in 2018, Dr. Cooper worked at Amgen, where he held positions of increasing responsibility, most recently serving as the Nephrology and Bone Global Medical Affairs Therapeutic Area Lead. During his tenure at Amgen, which began in 2010, Dr. Cooper oversaw multiple clinical trials spanning Amgen’s full portfolio of nephrology assets, and he provided medical leadership for the approval and launch of Parsabiv® for the treatment of hyperparathyroidism in patients with CKD. Before he began his industry career, Dr. Cooper spent more than 20 years in academia and as a practicing nephrologist. He holds a B.S. from the University of Miami and an M.D. from Yale University School of Medicine. He completed a residency in internal medicine and a fellowship in nephrology at Yale New Haven Hospital. A member of the American Society of Nephrology, International Society of Nephrology, and National Kidney Foundation, Dr. Cooper has author...